Blood safety is ensured by the rigorous selection of donors and biological tests. However, infectious agents can escape this detection and be transmitted to recipients during transfusion. Amotosalen is a derivative of psoralens that intercalates with nucleic acids and inactivates them after UV exposure; it therefore makes it possible to inhibit any replication of an infectious agent present. Preliminary studies have shown its safety and efficacy in preventing the transmission of infectious agents during the administration of labile blood products (fresh frozen plasma and platelet concentrates) as well as the absence of loss of efficacy (absence of loss of pro-aggregating and procoagulant properties) of the transfused products. In addition, there is a significant reduction in side effects for platelet concentrates, especially compared to irradiated concentrates. Treatment of platelet concentrates with Amotosalen may be responsible for a reduction in the platelet concentration in each concentrate with an overall decrease in efficiency and transfusion yield compared to untreated concentrates.
Study Type
OBSERVATIONAL
Enrollment
100
Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg
Strasbourg, France
RECRUITINGRetrospective study of the impact of the treatment with Amotosalen on the platelet transfusion practice in adult cardiac surgery unit
Time frame: Files analysed retrospectively from January 01, 2016 to June 30, 2019 will be examined
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.